198 related articles for article (PubMed ID: 37649456)
21. Immunotherapy improves disease prognosis by affecting the tumor microenvironment: A bibliometric study.
Wu X; Deng Z; Zhao Q
Front Immunol; 2022; 13():967076. PubMed ID: 36275770
[TBL] [Abstract][Full Text] [Related]
22. [Immunotherapy Based on Tumor Microenvironment in Renal Cell Carcinoma].
Han SC; Yin HQ; Xu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Apr; 44(2):305-312. PubMed ID: 35538767
[TBL] [Abstract][Full Text] [Related]
23. Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study.
Shen J; Shen H; Ke L; Chen J; Dang X; Liu B; Hua Y
Front Immunol; 2022; 13():815575. PubMed ID: 35173728
[TBL] [Abstract][Full Text] [Related]
24. The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy.
Lai Y; Tang F; Huang Y; He C; Chen C; Zhao J; Wu W; He Z
J Cell Physiol; 2021 Mar; 236(3):1616-1627. PubMed ID: 32783202
[TBL] [Abstract][Full Text] [Related]
25. A bibliometric and visualized research on global trends of immune checkpoint inhibitors related complications in melanoma, 2011-2021.
Zhang H; Shi Y; Ying J; Chen Y; Guo R; Zhao X; Jia L; Xiong J; Jiang F
Front Endocrinol (Lausanne); 2023; 14():1164692. PubMed ID: 37152956
[TBL] [Abstract][Full Text] [Related]
26. Bibliometric Analysis of Hotspots and Frontiers of Immunotherapy in Pancreatic Cancer.
Xu Q; Zhou Y; Zhang H; Li H; Qin H; Wang H
Healthcare (Basel); 2023 Jan; 11(3):. PubMed ID: 36766879
[TBL] [Abstract][Full Text] [Related]
27. Global Regulatory T-Cell Research from 2000 to 2015: A Bibliometric Analysis.
Zongyi Y; Dongying C; Baifeng L
PLoS One; 2016; 11(9):e0162099. PubMed ID: 27611317
[TBL] [Abstract][Full Text] [Related]
28. Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis.
Yang Y; Wang F
Front Oncol; 2022; 12():983892. PubMed ID: 36465399
[TBL] [Abstract][Full Text] [Related]
29. Emerging trends and hotspot in gut-lung axis research from 2011 to 2021: a bibliometrics analysis.
Wang Z; Bai C; Hu T; Luo C; Yu H; Ma X; Liu T; Gu X
Biomed Eng Online; 2022 Apr; 21(1):27. PubMed ID: 35449051
[TBL] [Abstract][Full Text] [Related]
30. Visual Analysis of Colorectal Cancer Immunotherapy: A Bibliometric Analysis From 2012 to 2021.
Ma L; Ma J; Teng M; Li Y
Front Immunol; 2022; 13():843106. PubMed ID: 35432385
[TBL] [Abstract][Full Text] [Related]
31. Current Trends and Future Directions of Malignancy After kidney Transplantation: A 1970-2022 Bibliometric Analysis.
Jiang F; Wang F; Zhang T; Dong H; Bai H; Chen L
Ann Transplant; 2024 Jan; 29():e942074. PubMed ID: 38163947
[TBL] [Abstract][Full Text] [Related]
32. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
[TBL] [Abstract][Full Text] [Related]
33. Immune-related adverse events: A bibliometric analysis.
Jiang ST; Liu YG; Zhang L; Sang XT; Xu YY; Lu X
Front Immunol; 2022; 13():1096806. PubMed ID: 36591239
[TBL] [Abstract][Full Text] [Related]
34. Emerging trends and hotspots in the links between the gut microbiota and MAFLD from 2002 to 2021: A bibliometric analysis.
Li Y; Zhou Y; Wang L; Lin X; Mao M; Yin S; Zhu L; Jiao Y; Yu W; Gao P; Yang L
Front Endocrinol (Lausanne); 2022; 13():990953. PubMed ID: 36329894
[TBL] [Abstract][Full Text] [Related]
35. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
36. Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios.
Cetin B; Kosar A
Int Urol Nephrol; 2019 Dec; 51(12):2107-2117. PubMed ID: 31468288
[TBL] [Abstract][Full Text] [Related]
37. Checkpoint Blockade - a New Treatment Paradigm in Renal Cell Carcinoma.
Grünwald V
Oncol Res Treat; 2016; 39(6):353-8. PubMed ID: 27259695
[TBL] [Abstract][Full Text] [Related]
38. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.
Sanchez A; Furberg H; Kuo F; Vuong L; Ged Y; Patil S; Ostrovnaya I; Petruzella S; Reising A; Patel P; Mano R; Coleman J; Russo P; Liu CH; Dannenberg AJ; Chan TA; Motzer R; Voss MH; Hakimi AA
Lancet Oncol; 2020 Feb; 21(2):283-293. PubMed ID: 31870811
[TBL] [Abstract][Full Text] [Related]
39. Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma-A network meta-analysis. Focus on cabozantinib combined with nivolumab.
Niewada M; Macioch T; Konarska M; Mela A; Goszczyński A; Przekopińska B; Rajkiewicz K; Wysocki P; Krzakowski M
Front Pharmacol; 2022; 13():1063178. PubMed ID: 36937206
[No Abstract] [Full Text] [Related]
40. Global research trends on the links between gut microbiota and cancer immunotherapy: A bibliometric analysis (2012-2021).
Yang S; Zhao S; Ye Y; Jia L; Lou Y
Front Immunol; 2022; 13():952546. PubMed ID: 36090978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
